Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen and Bio-Thera Report Progress On Tocilizumab

Firms Reveal Positive Phase III Data For Actemra/RoActemra Rival

Executive Summary

Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.

You may also be interested in...



Biogen Reiterates Byooviz Will Not Be Meaningful In 2022

Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.

FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?

Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”

Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US

Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel